308 related articles for article (PubMed ID: 1806441)
1. Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass.
Bianchi A; Omedé P; Attisano C; Camponi A; Dianzani U; Boccadoro M; Pileri A; Massaia M
Haematologica; 1991; 76(5):383-8. PubMed ID: 1806441
[TBL] [Abstract][Full Text] [Related]
2. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
Liberati AM; Schippa M; Portuesi MG; Grazia Proietti M; De Angelis V; Ferrajoli A; Cinieri S; Di Clemente F; Palmisano L; Berruto P
Haematologica; 1991; 76(5):375-82. PubMed ID: 1806440
[TBL] [Abstract][Full Text] [Related]
3. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
4. Effects of therapy with interferon-alpha on peripheral blood lymphocyte subsets and NK activity in patients with chronic hepatitis C.
Appasamy R; Bryant J; Hassanein T; Van Thiel DH; Whiteside TL
Clin Immunol Immunopathol; 1994 Dec; 73(3):350-7. PubMed ID: 7955564
[TBL] [Abstract][Full Text] [Related]
5. Recombinant alpha-2b-interferon may restore natural-killer activity in patients with B-chronic lymphocytic leukemia.
Villamor N; Reverter JC; Montserrat E; Urbano-Ispízua A; Vives-Corrons JL; Rozman C
Leukemia; 1992 Jun; 6(6):547-52. PubMed ID: 1376376
[TBL] [Abstract][Full Text] [Related]
6. Immunological response in chronic hepatitis C virus infection during interferon alpha therapy.
Panasiuk A; Prokopowicz D; Zak J
Hepatogastroenterology; 2004; 51(58):1088-92. PubMed ID: 15239252
[TBL] [Abstract][Full Text] [Related]
7. Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
Riley CH; Hansen M; Brimnes MK; Hasselbalch HC; Bjerrum OW; Straten PT; Svane IM; Jensen MK
Eur J Haematol; 2015 Mar; 94(3):227-34. PubMed ID: 25082025
[TBL] [Abstract][Full Text] [Related]
8. Interferon gamma as immunomodulator in a patient with multiple myeloma.
Kamińska T; Dmoszyńska A; Cioch M; Hus I; Jawniak D; Szuster-Ciesielska A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 1999; 47(2):107-12. PubMed ID: 10202563
[TBL] [Abstract][Full Text] [Related]
9. Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma.
Maxwell W; McDevitt J; Reid I; Sharpe I; Feighery C; Tanner WA; Emmons R; Monson JR
Eur J Surg Oncol; 1993 Jun; 19(3):265-72. PubMed ID: 8314385
[TBL] [Abstract][Full Text] [Related]
10. Immune defects in families and patients with xeroderma pigmentosum and trichothiodystrophy.
Mariani E; Facchini A; Honorati MC; Lalli E; Berardesca E; Ghetti P; Marinoni S; Nuzzo F; Astaldi Ricotti GC; Stefanini M
Clin Exp Immunol; 1992 Jun; 88(3):376-82. PubMed ID: 1535035
[TBL] [Abstract][Full Text] [Related]
11. The lack of NK cytotoxicity associated with fresh HUCB may be due to the presence of soluble HLA in the serum.
Webb BJ; Bochan MR; Montel A; Padilla LM; Brahmi Z
Cell Immunol; 1994 Dec; 159(2):246-61. PubMed ID: 7994757
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
13. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Klasa RJ; Silver HK; Kong S
Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.
Millar BC; Bell JB; Powles RL
Br J Cancer; 1996 Jan; 73(2):236-40. PubMed ID: 8546912
[TBL] [Abstract][Full Text] [Related]
15. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the therapeutic potential of cytokines, cytotoxic drugs and effector cell populations for the treatment of multiple myeloma using the 5T33 murine myeloma model.
Manning LS; Chamberlain NL; Leahy MF; Cordingley FT
Immunol Cell Biol; 1995 Aug; 73(4):326-32. PubMed ID: 7493769
[TBL] [Abstract][Full Text] [Related]
17. Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy.
Favrot M; Capdeville R; Combaret V; Zhou DC; Clapisson G; Banchereau J; Franks CR; Chouaib S; Blay JY; Philip T
Eur Cytokine Netw; 1990; 1(3):141-7. PubMed ID: 2129798
[TBL] [Abstract][Full Text] [Related]
18. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
19. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells.
Rossi EA; Rossi DL; Stein R; Goldenberg DM; Chang CH
Cancer Res; 2010 Oct; 70(19):7600-9. PubMed ID: 20876805
[TBL] [Abstract][Full Text] [Related]
20. 2',5'-Oligoadenylate synthetase levels in patients with multiple myeloma receiving maintenance therapy with interferon alpha 2b do not correlate with clinical response.
Millar BC; Bell JB
Br J Cancer; 1995 Dec; 72(6):1525-30. PubMed ID: 8519671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
